Browsing Tag
Summit Therapeutics
8 posts
Summit Therapeutics (NASDAQ: SMMT) gives back most of 23% spike after AstraZeneca’s $2bn investment
AstraZeneca is investing $2 billion in Summit Therapeutics at an $18.36 common-equivalent price, yet Summit closed at only $16.39 after touching $19.01, showing that strategic validation has not erased the clinical and regulatory risk around ivonescimab.
Akeso’s ivonescimab beats Keytruda on overall survival in China as Summit Therapeutics’ global wager gains another proof point
Akeso's HARMONi-2 trial reported median overall survival of 30.8 months for ivonescimab against 22.6 months for pembrolizumab, strengthening the scientific case while leaving global validation in Summit Therapeutics' territories as the crucial commercial test.
Has Akeso Inc. just exposed the next weak spot in standard lung cancer treatment?
Find out how Akeso Inc.’s ivonescimab survival data could reshape lung cancer treatment and challenge PD-1 drug combinations.
Summit Therapeutics launches global Phase III HARMONi-GI3 trial as ivonescimab enters colorectal cancer race
Find out how Summit Therapeutics and Akeso are betting on ivonescimab’s expansion into colorectal cancer and why investors see it as a defining moment for the biotech’s future.
Top gainers on Wall Street : Ferguson, MoonLake, Summit lead the rally
Ferguson, MoonLake, and Summit Therapeutics led U.S. markets on June 3 with gains over 15%. Find out what triggered this breakout rally.
Wall Street turmoil: These 25 stocks plunged hardest amid Trump tariffs and sector shocks
Allegro MicroSystems, MP Materials, ZEEKR, and Albertsons led losses on April 15, 2025, as trade tensions, sector headwinds, and investor caution triggered a widespread selloff across US markets.
Biotech and Argentina-linked stocks lead April 11 US market rebound amid volatility and tariff headwinds
Discover why biotech, energy, and Argentina-linked stocks soared on April 11, 2025, as US markets rebounded despite global tariff tensions.
Summit Therapeutics set to begin HARMONi trial of Ivonescimab in EGFR-mutant lung cancer
Summit Therapeutics Inc. has announced a significant milestone in its oncology development efforts, completing patient enrollment for the…